GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Ironwood Pharmaceuticals
Ironwood Pharmaceuticals specializes in treating gastrointestinal diseases. Its stock price is primarily driven by sales of its key drug, Linzess. The chart is a story of growth driven by the success of a single blockbuster and efforts to expand its product portfolio.
Share prices of companies in the market segment - Pharma git
Ironwood Pharmaceuticals is a pharmaceutical company focused on developing and commercializing drugs for the treatment of gastrointestinal diseases. We have classified it in the Pharma: Gastrointestinal category. The chart below shows how investors value companies in this broad and stable area of medicine.
Broad Market Index - GURU.Markets
Ironwood Pharmaceuticals is a pharmaceutical company focused on developing and commercializing drugs for the treatment of gastrointestinal diseases. It is a component of the GURU.Markets index. The chart below represents the market. See how this company's stock compares to the pharmaceutical sector.
Change in the price of a company, segment, and market as a whole per day
IRWD - Daily change in the company's share price Ironwood Pharmaceuticals
For Ironwood, a biopharmaceutical company, change_co is a measure of the company's response to the commercial success of its drugs. Daily fluctuations reflect sensitivity to sales data and patent disputes. This metric is important for analyzing stable but focused pharmaceutical companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma git
Ironwood Pharmaceuticals, Inc. is a pharmaceutical company. This chart highlights the sector's high volatility. Comparing it to IRWD, which focuses on gastrointestinal diseases, helps assess its risk compared to more diversified pharmaceutical companies.
Daily change in the price of a broad market stock, index - GURU.Markets
Ironwood is a biopharmaceutical company specializing in gastrointestinal treatments. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Ironwood's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Ironwood Pharmaceuticals
For Ironwood Pharmaceuticals, the year-over-year performance is the story of its flagship gastrointestinal drug, LINZESS. Its market capitalization growth over the past 12 months is directly linked to the sales volume of this blockbuster, as well as to progress in research into its use in new indications, which is key to extending its life cycle.
Annual dynamics of market capitalization of the market segment - Pharma git
Ironwood Pharmaceuticals, Inc. is a commercial pharmaceutical company focused on treating gastrointestinal diseases. Its success depends on the commercialization of its key drug. The chart shows how its niche strategy and competitive environment influence its performance in the pharmaceutical sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Ironwood is a biopharmaceutical company whose stock performance is driven by the success of its drug sales and progress in research. The company's business is not dependent on economic cycles. The chart reflects biotech events rather than macroeconomic data, making it a non-cyclical growth story.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Ironwood Pharmaceuticals
Ironwood, a pharmaceutical company, has a market capitalization dependent on its product cycle. The monthly fluctuations in the chart reflect sales data for its flagship drug, Linzess, a gastrointestinal disorder treatment that is the market leader.
Monthly dynamics of market capitalization of the market segment - Pharma git
Ironwood Pharmaceuticals specializes in the treatment of gastrointestinal diseases. This segment of the pharmaceutical market is characterized by stable demand but also high competition. The chart below shows how investors assessed the prospects of companies offering solutions for chronic gastrointestinal diseases and their commercial potential.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Ironwood Pharmaceuticals specializes in gastrointestinal medications. It's a commercial company, and its stock price is driven by sales of its key drug, Linzess. It's a focused company, where quarterly sales reports carry more weight than market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, a gastrointestinal company, is news-sensitive. Weekly price movements depend on sales data for its key drug, Linzess, and the results of clinical trials of new drugs. The chart below shows how short-term commercial and scientific events influence the company's valuation.
Weekly dynamics of market capitalization of the market segment - Pharma git
How typical are Ironwood Pharmaceuticals' dynamics for the pharmaceutical sector? This chart compares the weekly stock price movements of this gastrointestinal-focused company to the industry average. This helps us understand whether its reaction to sales and research news is typical, or whether its niche specialization creates a unique trajectory.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Ironwood Pharmaceuticals specializes in gastrointestinal drugs. This chart compares its weekly performance to the market. It helps understand how its business, focused on a few approved products, provides stability compared to research-stage biotechs.
Market capitalization of the company, segment and market as a whole
IRWD - Market capitalization of the company Ironwood Pharmaceuticals
Ironwood Pharmaceuticals' price chart reflects its focus on treating gastrointestinal diseases. The company's market capitalization is built on the success of its flagship drug, Linzess. The dynamics clearly demonstrate how investors assess the life cycle of this blockbuster and the prospects for its new developments in the same area.
IRWD - Share of the company's market capitalization Ironwood Pharmaceuticals within the market segment - Pharma git
Ironwood Pharmaceuticals holds a dominant market share in drugs for the treatment of gastrointestinal disorders such as irritable bowel syndrome (IBS) through its flagship product, Linzess.
Market capitalization of the market segment - Pharma git
This chart shows the total value of pharmaceutical companies specializing in gastrointestinal diseases. Ironwood Pharmaceuticals is a leader in this field. The dynamics in the chart are closely linked to the commercial success and life cycle of its key drug, Linzess.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes the market value of gastrointestinal diseases. Ironwood Pharmaceuticals' market cap is the valuation of its drugs, which help millions of people. The line shows how focusing on common but often ignored health problems is creating a significant market share in the global pharmaceutical industry.
Book value capitalization of the company, segment and market as a whole
IRWD - Book value capitalization of the company Ironwood Pharmaceuticals
Ironwood Pharmaceuticals' book value represents its intellectual capital. The chart below reflects the valuation of its rights to the gastrointestinal drug LINZESS®. The dynamics demonstrate how the drug's commercial success shapes the company's core tangible asset.
IRWD - Share of the company's book capitalization Ironwood Pharmaceuticals within the market segment - Pharma git
Ironwood Pharmaceuticals' tangible assets include its R&D infrastructure, which is focused on treating gastrointestinal diseases. The chart shows the company's share of this highly specialized scientific base, which forms the foundation for the development of drugs that improve the quality of life for millions of patients.
Market segment balance sheet capitalization - Pharma git
Below you can see the overall book value of the pharmaceutical sector. Against this backdrop, Ironwood, with its focus on gastrointestinal diseases, is moderately capital-intensive. Commercializing its products requires investments in marketing and supply chains, which weighs down its balance sheet compared to R&D companies.
Book value of all companies included in the broad market index - GURU.Markets
Ironwood Pharmaceuticals is a company focused on treating gastrointestinal diseases. Its primary asset is the rights to the drug Linzess. The company's balance sheet is essentially the value of this successful drug, which addresses a very real and widespread health problem.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Ironwood Pharmaceuticals
Ironwood's balance sheet represents the value of its rights to the drug Linzess. Market valuation reflects the future cash flows from this drug. The MvsBCap_Co chart shows how investors assess the stability and longevity of this revenue stream for a single-product company.
Market to book capitalization ratio in a market segment - Pharma git
Ironwood Pharmaceuticals specializes in gastrointestinal drugs. The chart shows how the market values its main commercial product, Linzess, and its development pipeline. The premium to book value reflects the value of its intellectual property.
Market to book capitalization ratio for the market as a whole
Ironwood Pharmaceuticals specializes in the development and commercialization of drugs for the treatment of gastrointestinal diseases. Its flagship product is Linzess. This chart helps assess how the market perceives companies focused on treating common but non-life-threatening conditions that improve patients' quality of life.
Debts of the company, segment and market as a whole
IRWD - Company debts Ironwood Pharmaceuticals
For Ironwood Pharmaceuticals, a company focused on gastrointestinal diseases, debt is a marketing and R&D tool. This chart shows how the company finances the promotion of its lead drug and the development of new drugs. In the pharmaceutical industry, debt helps maximize revenue from existing products and invest in future ones.
Market segment debts - Pharma git
Ironwood Pharmaceuticals specializes in gastrointestinal drugs. This chart illustrates how a pharmaceutical company with a commercial product manages its finances, reinvesting revenue into marketing and drug development to expand its portfolio.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Ironwood Pharmaceuticals
Ironwood Pharmaceuticals specializes in gastrointestinal drugs. This chart shows how the company balances debt and equity. For a pharmaceutical company whose revenue depends on the success of one or two key drugs, debt management is critical to funding the marketing and research of new drugs.
Market segment debt to market segment book capitalization - Pharma git
Ironwood Pharmaceuticals specializes in drugs for gastrointestinal disorders such as irritable bowel syndrome. This is a large market with an unmet need. The chart shows how the company's debt load compares to its overall market capitalization and financial standards in the pharmaceutical industry.
Debt to book value of all companies in the market
Ironwood Pharmaceuticals (IRWD) specializes in drugs for the treatment of gastrointestinal diseases. Having a commercial product provides the company with stable cash flow. This chart shows the overall debt burden of the economy. It allows one to compare the debt position of IRWD, which has revenue, with that of biopharmaceutical companies in the development stage.
P/E of the company, segment and market as a whole
P/E - Ironwood Pharmaceuticals
This chart shows the valuation of Ironwood Pharmaceuticals, a company focused on treating gastrointestinal diseases. Its P/E is driven by sales of its lead drug, Linzess. Its growth is driven by its expanded use, while risks stem from future generic competition after patent expiration.
P/E of the market segment - Pharma git
This chart illustrates the average P/E for pharmaceutical companies. For Ironwood, with its focus on gastrointestinal diseases, this is an important benchmark. Comparing its P/E to the industry average helps understand how investors assess the commercial potential of its lead drug and the risks associated with future patent loss.
P/E of the market as a whole
Ironwood Pharmaceuticals is a pharmaceutical company focused on developing and commercializing drugs for the treatment of gastrointestinal diseases, such as irritable bowel syndrome. This chart, reflecting overall sentiment, helps understand how investors value specialty pharmaceutical companies with established products.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Ironwood Pharmaceuticals
Ironwood Pharmaceuticals is a commercial pharmaceutical company focused on the treatment of gastrointestinal diseases. Its lead product, Linzess, is intended for the treatment of irritable bowel syndrome with constipation. This chart reflects sales expectations for this drug. The valuation is highly dependent on its commercial success and the competitive environment in the gastrointestinal drug market.
%20P%2FE%20Ironwood%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Ironwood-Pharmaceuticals&v=1772708270177 "Chart of the company's future (projected) P/E Ironwood Pharmaceuticals")
Future (projected) P/E of the market segment - Pharma git
Ironwood Pharmaceuticals specializes in gastrointestinal medications. This chart compares the company's future profitability expectations with the pharmaceutical sector average. It reflects the market's confidence in the success of its lead drug, LINZESS, and other drugs in development for this large market.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20git&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-git&v=1772708270177 "Future (projected) P/E graph of the market segment - Pharma git")
Future (projected) P/E of the market as a whole
Ironwood Pharmaceuticals specializes in gastrointestinal medications. The company's success depends on sales of its flagship drug, Linzess. This chart of overall market expectations serves as a backdrop for investors to assess the stability of demand for medications that address chronic health issues.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772708270178 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Ironwood Pharmaceuticals
Ironwood Pharmaceuticals is a commercial biopharmaceutical company specializing in the treatment of gastrointestinal diseases. Its lead drug, Linzess, is used to treat irritable bowel syndrome. The company's profits depend on sales of this drug and the success of its development.
Profit of companies in the market segment - Pharma git
Ironwood Pharmaceuticals specializes in gastrointestinal medications. Focusing on a single therapeutic area allows the company to deepen its expertise. This chart illustrates how niche pharmaceutical companies can achieve success by solving specific problems and contributing to overall industry profitability.
Overall market profit
Ironwood Pharmaceuticals specializes in medications for gastrointestinal diseases. Demand for these medications is driven by patient needs, not the state of the economy. This makes Ironwood's business non-cyclical and resilient to economic downturns, as reflected in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Ironwood Pharmaceuticals
Ironwood Pharmaceuticals specializes in gastrointestinal medications, with its flagship product, Linzess. This chart shows revenue expectations, which are entirely dependent on sales volumes for this drug and the success of its gastrointestinal drug development program.
%20profit%20of%20the%20company%20Ironwood%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Ironwood-Pharmaceuticals&v=1772708270180 "Graph of future (projected) profit of the company Ironwood Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharma git
Ironwood Pharmaceuticals is a commercial pharmaceutical company focused on the treatment of gastrointestinal diseases. Its flagship product is LINZESS. This chart shows the revenue forecast for the entire gastrointestinal pharmaceutical sector. It reflects expected demand for treatments for conditions such as irritable bowel syndrome.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20git&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-git&v=1772708270182 "Graph of future (predicted) profits of companies in a market segment - Pharma git")
Future (predicted) profit of the market as a whole
Ironwood Pharmaceuticals specializes in medications for gastrointestinal diseases. Its sales are driven by prescription volume and insurance coverage. Economic cycles, as reflected here, affect sales indirectly through employment levels (and, therefore, insurance coverage) and overall patient spending on medications.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772708270183 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Ironwood Pharmaceuticals
Ironwood Pharmaceuticals is a commercial pharmaceutical company focused on treating gastrointestinal diseases. Its flagship product is Linzess, a treatment for irritable bowel syndrome. This chart shows how investors view the sales of this successful drug and the potential of the company's other developments.
P/S market segment - Pharma git
Ironwood Pharmaceuticals is a gastroenterology pharmaceutical company specializing in the development and commercialization of drugs for the treatment of gastrointestinal (GI) diseases, such as irritable bowel syndrome. This chart shows the average valuation in the sector, helping to understand how the market views Ironwood's product portfolio and leadership in the GI niche.
P/S of the market as a whole
Ironwood Pharmaceuticals is a pharmaceutical company specializing in the development and commercialization of drugs for the treatment of gastrointestinal diseases, such as irritable bowel syndrome. This market valuation chart helps understand how investors view the company, whose revenue depends on the successful sales of one or more key drugs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Ironwood Pharmaceuticals
Ironwood Pharmaceuticals specializes in gastrointestinal medications. Future revenue depends on sales of its key drug. This chart reflects investor expectations for its market potential and patient growth.
%20P%2FS%20Ironwood%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Ironwood-Pharmaceuticals&v=1772708270188 "The graph of the company's future (projected) P/S Ironwood Pharmaceuticals")
Future (projected) P/S of the market segment - Pharma git
Ironwood Pharmaceuticals is a pharmaceutical company focused on treating gastrointestinal diseases. This chart compares market expectations for its future revenue with those of other companies in the sector. The estimate reflects investor opinion on the sales of its key drug, LINZESS, and its clinical pipeline.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20git&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-git&v=1772708270189 "Future (projected) P/S market segment graph - Pharma git")
Future (projected) P/S of the market as a whole
Ironwood Pharmaceuticals specializes in medications for gastrointestinal diseases. Demand for its products is driven by medical needs. However, the overall economic optimism reflected in this chart is impacting healthcare funding and patient willingness to see a doctor, which supports stable drug sales.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772708270190 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Ironwood Pharmaceuticals
Ironwood Pharmaceuticals is a commercial pharmaceutical company specializing in the treatment of gastrointestinal diseases. Its revenue is generated from sales and royalties from its lead drug, Linzess. This chart shows the commercial success of this drug, which is a leader in its therapeutic area.
Sales of companies in the market segment - Pharma git
Ironwood Pharmaceuticals is a commercial pharmaceutical company focused on the treatment of gastrointestinal diseases. Its flagship product, Linzess, is a market leader in irritable bowel syndrome (IBS). Its revenue is generated from sales of this drug. This chart shows the state of the large gastrointestinal drug market, where Ironwood holds a strong position.
Overall market sales
Ironwood Pharmaceuticals specializes in medications for gastrointestinal diseases. Demand for its products is driven by medical needs, not economic cycles. However, the overall economic situation reflected here impacts the healthcare system, insurance coverage, and patient access to medications.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Ironwood Pharmaceuticals
Ironwood Pharmaceuticals is a commercial pharmaceutical company specializing in the treatment of gastrointestinal diseases. Its flagship product is Linzess, a drug for the treatment of irritable bowel syndrome. This chart shows analysts' expectations for continued sales growth for Linzess and the success of new drugs in development.
%20sales%20of%20the%20company%20Ironwood%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Ironwood-Pharmaceuticals&v=1772708270192 "Schedule of future (projected) sales of the company Ironwood Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharma git
Ironwood Pharmaceuticals is a pharmaceutical company focused on treating gastrointestinal diseases. The data in this chart shows the outlook for the pharmaceutical industry. This allows one to assess how sales of its flagship irritable bowel syndrome drug and its portfolio expansion efforts impact the company's long-term prospects.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20git&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-git&v=1772708270193 "Schedule of future (projected) sales of companies in the market segment - Pharma git")
Future (projected) sales of the market as a whole
Ironwood Pharmaceuticals specializes in gastrointestinal medications. This graph, reflecting healthcare costs, is important to the company. Stable healthcare funding and the willingness of insurance companies to cover chronic disease treatments ensure robust demand for Ironwood's commercialized medications.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772708270194 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Ironwood Pharmaceuticals
Ironwood Pharmaceuticals is a pharmaceutical company focused on treating gastrointestinal diseases. Its business is built on the commercialization of approved drugs and the development of new ones. This chart shows how the company converts sales of its gastrointestinal drugs into profits, which are reinvested in further research and development.
Market segment marginality - Pharma git
Ironwood Pharmaceuticals specializes in drugs for the treatment of gastrointestinal disorders, such as irritable bowel syndrome. Their flagship product is LINZESS. This chart shows how successfully the company is commercializing its lead drug and managing costs to maintain profitability in its therapeutic niche.
Market marginality as a whole
#VALUE!
Employees in the company, segment and market as a whole
Number of employees in the company Ironwood Pharmaceuticals
Ironwood Pharmaceuticals is a commercial pharmaceutical company specializing in gastrointestinal medications. This chart shows the company's commercial and R&D teams. The size of the team reflects the company's efforts to advance approved products and develop new drugs in its niche.
Share of the company's employees Ironwood Pharmaceuticals within the market segment - Pharma git
Ironwood Pharmaceuticals is a gastroenterology company focused on developing and commercializing drugs for the treatment of gastrointestinal diseases. This chart shows its market share in a narrow niche of the pharmaceutical industry. It reflects the team's work on developing new treatments for common conditions like irritable bowel syndrome.
Number of employees in the market segment - Pharma git
Ironwood Pharmaceuticals specializes in medications for gastrointestinal disorders, such as irritable bowel syndrome. This chart shows employment in the pharmaceutical industry. The company's stable workforce of commercial and medical specialists reflects its focus on promoting its key drug and raising awareness of gastrointestinal disorders.
Number of employees in the market as a whole
Ironwood Pharmaceuticals is a pharmaceutical company focused on treating gastrointestinal diseases. Its flagship drug, Linzess, is designed to treat irritable bowel syndrome with constipation. This chart shows overall employment, and specialized pharmaceutical companies like Ironwood contribute by creating jobs in drug research, marketing, and sales.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Ironwood Pharmaceuticals (IRWD)
Ironwood Pharmaceuticals, Inc. is a commercial pharmaceutical company focused on gastrointestinal diseases. Its business model is based on patented products. This chart demonstrates high capitalization per employee. A small sales and marketing team can market a product with multimillion-dollar revenues, demonstrating the effectiveness of intellectual property.
%20of%20the%20company%20Ironwood%20Pharmaceuticals%20(IRWD)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Ironwood-Pharmaceuticals-IRWD&v=1772708270199 "Chart of market capitalization per employee (in thousands of dollars) of the company Ironwood Pharmaceuticals (IRWD)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma git
Ironwood Pharmaceuticals specializes in gastrointestinal medications, with its flagship product, Linzess. For a pharmaceutical company with a single blockbuster, this metric reflects its commercial success. The chart shows how effectively the company monetizes its flagship drug through its commercial and scientific teams.
%20by%20market%20segment%20-%20Pharma%20git&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-git&v=1772708270200 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma git")
Market capitalization per employee (in thousands of dollars) for the overall market
Ironwood Pharmaceuticals specializes in gastrointestinal medications. Its flagship product is Linzess. The company's value is closely tied to sales of this drug. This chart shows how the market values the team's ability to maximize the potential of its core product and develop new ones.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772708270200 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Ironwood Pharmaceuticals (IRWD)
Ironwood Pharmaceuticals (IRWD) is a biopharmaceutical company focused on gastrointestinal treatments (their lead product is Linzess). This chart shows how successfully they are commercializing their flagship drug. It measures how much revenue their focused team is generating.
%20Chart%20Ironwood%20Pharmaceuticals%20(IRWD)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Ironwood-Pharmaceuticals-IRWD&v=1772708270201 "Company Profit Per Employee (in thousands of dollars) Chart Ironwood Pharmaceuticals (IRWD)")
Profit per employee (in thousands of dollars) in the market segment - Pharma git
Ironwood Pharmaceuticals focuses on gastrointestinal treatments. Their flagship product is LINZESS, a treatment for irritable bowel syndrome. Their business is the commercialization of this drug. This chart shows the benchmark for employee profitability in the pharmaceutical industry. It's important for assessing how effectively the Ironwood team is monetizing their blockbuster.
%20in%20the%20market%20segment%20-%20Pharma%20git&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-git&v=1772708270201 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma git")
Profit per employee (in thousands of dollars) for the market as a whole
Ironwood Pharmaceuticals (IRWD) is a pharmaceutical company focused on treating gastrointestinal diseases. Their flagship product is LINZESS, which they market through a partnership. This is the commercial stage. This chart shows how well the company generates revenue (primarily royalties and partner payments) per headcount (R&D, G&A).
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772708270202 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Ironwood Pharmaceuticals (IRWD)
Ironwood Pharmaceuticals is a commercial pharmaceutical company specializing in gastrointestinal medications. This chart demonstrates the effectiveness of its business model. It reflects how successfully its sales team promotes its key drug to physicians, generating stable revenue.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Ironwood-Pharmaceuticals-IRWD&v=1772708270202 "Sales chart per company employee Ironwood Pharmaceuticals (IRWD)")
Sales per employee in the market segment - Pharma git
Ironwood Pharmaceuticals (IRWD) is a pharmaceutical company focused on treating gastrointestinal diseases. Their flagship product is Linzess (in partnership with AbbVie). This chart shows the revenue (royalties and sales) generated by each employee. It's an indicator of the commercial success of their flagship drug.
Sales per employee for the market as a whole
Ironwood Pharmaceuticals (IRWD) is a commercial-stage biotech focused on the gastrointestinal tract. Their lead product is Linzess. This chart shows how well their commercial team and R&D department are generating revenue (primarily through royalties from partner AbbVie) from this single, yet highly successful, blockbuster drug.
Short shares by company, segment and market as a whole
Shares shorted by company Ironwood Pharmaceuticals (IRWD)
Ironwood Pharmaceuticals is a biopharmaceutical company focused on treating gastrointestinal diseases. Their flagship drug is Linzess (for IBS). This chart shows bearish bets. The shorts may be driven by concerns that Linzess will hit the patent cliff (generics) sooner than expected, which would wipe out the company's main source of revenue.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Ironwood-Pharmaceuticals-IRWD&v=1772708270207 "Short Shares Chart for the Company Ironwood Pharmaceuticals (IRWD)")
Shares shorted by market segment - Pharma git
Ironwood (IRWD) is a pharmaceutical company focused on gastrointestinal diseases, best known for its IBS drug Linzess. This chart shows bets against the specialty pharmaceutical sector. The rising "bet against" the industry may reflect investor concerns about intense competition in gastrointestinal treatments and the company's reliance on a single product.
Shares shorted by the overall market
Ironwood Pharmaceuticals has a commercial product, LINZESS, for the treatment of gastrointestinal disorders. Its revenue is stable and driven by patient demand, making the business defensive. High market anxiety (shown in this chart) has less of an impact on companies with established sales of non-discretionary drugs, which is a distinct advantage for IRWD.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Ironwood Pharmaceuticals (IRWD)
Ironwood Pharmaceuticals (IRWD) is a pharmaceutical company focused on treating gastrointestinal diseases. Their main product is LINZESS, a drug for the treatment of irritable bowel syndrome (IBS). This chart measures momentum. It shows "overbought" (above 70) due to strong LINZESS sales data or "oversold" (below 30) due to concerns about patent disputes.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Ironwood-Pharmaceuticals-IRWD&v=1772708270213 "RSI 14 indicator chart for the company's stock Ironwood Pharmaceuticals (IRWD)")
RSI 14 Market Segment - Pharma git
Ironwood (IRWD) is a pharmaceutical company focused on gastrointestinal (GI) treatments, best known for its IBS treatment, Linzess. This chart tracks overall sentiment in the Pharma/GI sector. It helps investors understand whether IRWD's performance reflects sales of its flagship product or whether the entire industry is overheated or oversold.
RSI 14 for the overall market
Ironwood (IRWD), a pharmaceutical company. This chart reflects the mood in the sector. During periods of euphoria, investors are willing to fund the R&D of new drugs. In times of panic, they seek companies with existing, cash-generating sales (like IRWD). Its business is "defensive," as demand for gastrointestinal drugs is not dependent on the economy.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast IRWD (Ironwood Pharmaceuticals)
Ironwood Pharmaceuticals is a biopharmaceutical company specializing in the treatment of gastrointestinal (GI) diseases. Its flagship product is LINZESS, a treatment for IBS. This chart shows the average target price analysts are predicting based on LINZESS sales growth and new drug development.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-IRWD-Ironwood-Pharmaceuticals&v=1772708270217 "A chart showing analyst consensus forecasts for the expected stock price. IRWD (Ironwood Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price IRWD (Ironwood Pharmaceuticals)
Ironwood (IRWD) is a pharmaceutical company focused on gastrointestinal diseases. Its main asset is the blockbuster drug Linzess (for the treatment of constipation associated with IBS), which it markets jointly with AbbVie. This chart shows the difference between the consensus estimate and the price. It reflects analysts' confidence in the drug's continued growth and longevity.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-IRWD-Ironwood-Pharmaceuticals&v=1772708270218 "A chart showing the difference between the consensus forecast and the actual stock price. IRWD (Ironwood Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharma git
Ironwood (IRWD) is a pharma company focused on the gastrointestinal tract. Its flagship product, Linzess (in partnership with AbbVie), is a blockbuster treatment for IBS (irritable bowel syndrome) with constipation. This chart shows analysts' overall expectations for the entire pharmaceutical (gastrointestinal) sector. It reflects whether experts believe this massive market can grow.
Analysts' consensus forecast for the overall market share price
Ironwood is a "niche" "pharma" focused on "gastrointestinal" "diseases" (its drug "Linzess"). This chart of overall market sentiment is important. "Demand" for the "treatment" of "chronic" "diseases" is "protected." In a "recession" (pessimism), "investors" "value" the "non-cyclical" and "stable" "cash" "flow" of IRWD's "business."
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Ironwood Pharmaceuticals
Ironwood (IRWD) is a biopharmaceutical company focused on the gastrointestinal tract. Their cash cow is Linzess, a blockbuster drug (which they share with AbbVie) for the treatment of IBS (irritable bowel syndrome). This chart is an indicator of their strength. It measures the steady growth of their cash cow (Linzess) and their efforts to leverage this profitability into developing new gastrointestinal drugs.
AKIMA Market Segment Index - Pharma git
Ironwood Pharmaceuticals specializes in treating gastrointestinal disorders. Their flagship product is LINZESS, a medication for irritable bowel syndrome (IBS). This chart shows the average pharmaceutical sector index. It allows you to assess how Ironwood, with its focus on the gastrointestinal tract, compares to the average pharmaceutical company.
The AKIM Index for the overall market
Ironwood Pharmaceuticals is a gastroenterology company known for its blockbuster drug Linzess (an IBS treatment). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this profitable pharma company, which is seeking to diversify its portfolio, compares to overall economic trends in the sector.
